Clinical Trial Update: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. [Phase 3]

View source ↗

Summary

Phase 3 trial results for olaparib maintenance monotherapy in BRCA-mutated ovarian cancer after first-line platinum chemotherapy have been posted. The study eva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Newly Diagnosed, Advanced Ovarian Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-07-09